Pfizer Inc. (PFE) Holdings Trimmed by FDx Advisors Inc.

Share on StockTwits

FDx Advisors Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 243,284 shares of the biopharmaceutical company’s stock after selling 138,520 shares during the period. FDx Advisors Inc.’s holdings in Pfizer were worth $8,826,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PFE. BlackRock Inc. raised its stake in shares of Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after acquiring an additional 6,785,335 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Pfizer by 0.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock valued at $2,245,053,000 after acquiring an additional 160,730 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after acquiring an additional 4,998,981 shares during the period. Fisher Asset Management LLC raised its stake in shares of Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after acquiring an additional 1,671,311 shares during the period. Finally, LSV Asset Management raised its stake in shares of Pfizer by 2.7% in the 2nd quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock valued at $1,334,182,000 after acquiring an additional 973,497 shares during the period. 68.96% of the stock is currently owned by institutional investors.

Several research firms recently issued reports on PFE. Citigroup set a $37.00 price target on shares of Pfizer and gave the stock a “sell” rating in a research note on Tuesday. BMO Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $47.00 to $46.00 in a research note on Thursday, November 1st. They noted that the move was a valuation call. Societe Generale set a $43.00 price target on shares of Pfizer and gave the stock a “hold” rating in a research note on Thursday, November 1st. Credit Suisse Group reaffirmed a “neutral” rating and set a $40.00 price target on shares of Pfizer in a research note on Tuesday, October 30th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research note on Tuesday, October 30th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $42.67.

Shares of PFE stock opened at $43.01 on Wednesday. The firm has a market cap of $255.56 billion, a price-to-earnings ratio of 16.23, a P/E/G ratio of 2.16 and a beta of 0.88. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. Equities analysts forecast that Pfizer Inc. will post 3 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.16%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Pfizer Inc acquired 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the acquisition, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The disclosure for this purchase can be found here. 0.06% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This story was published by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://weekherald.com/2018/11/07/pfizer-inc-pfe-holdings-trimmed-by-fdx-advisors-inc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply